Shots:
- Fujifilm and Opsis to receive $30M up front and ~$40M as R&D and part of manufacturing funding for the development of 3 programs. The companies are eligible to receive development & commercial milestones along with royalties on a per-program basis
- BlueRock to get an option to license the 3 programs on a program-by-program basis and will be responsible for development & commercialization of the licensed products. Fujifilm and BlueRock will share manufacturing responsibilities and commercial supply, with Fujifilm responsible for clinical supply
- The companies will combine their expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases
Click here to read full press release/ article | Ref: Bayer | Image: PRNewswire
The post BlueRock Collaborates with Fujifilm and Opsis to Discover and Develop Cell Therapies for Eye Diseases first appeared on PharmaShots.
